FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2272129917> ?p ?o ?g. }

• W2272129917 endingPage "22207" @default.
• W2272129917 startingPage "22207" @default.
• W2272129917 abstract "22207 Background: Triple negative breast cancer (TN), defined as estrogen (ER), progesterone (PR) and HER-2 negative, accounts for 15% of breast cancer and is more common in premenopausal African American (AA) females. TN is associated with high rate of local and systemic relapse. The purpose of this study was to determine the incidence of TN in a cohort breast cancer patients presented at WCI. We also reviewed age, race, grade and stage at the diagnosis of TN. Methods: Consecutive medical records of patients diagnosed with invasive breast carcinoma (IBC) between 1/2004 and 12/2006 were obtained from cancer registry at WCI, Washington Hospital Center. Patients were classified having TN if they were negative for all 3 receptors (ER, PR and HER-2) or non triple negative (NTN) if they were positive for any of the 3 markers. Results: 617 patients were identified as new patients with IBC over 3 yrs. 586 (84%) women were African American (AA) and 131 (16%) of other ethnicities (W). 147 (22%) were classified as TN and 524 (78%) as NTN. Of the TN, 135 (90%) were AA and 12 (10%) W. Median age at the time of diagnosis of TN for AA was 55 yrs vs 59 yrs for W. 56 (38%) were <50 yrs, 73(50%) 51–70 yrs and 18 (12%) >71 yrs. 129 (88%) of the TN were grade 3, 17(11%) grade 2 and 1(1%) grade 1. Stage distribution in TN: Stage I- 46 (31%); Stage II- 59 (40%); Stage III- 28 (19%); Stage IV- 7 (5%). 7(4%) were not staged. All patients except 7 had either lumpectomy with radiation or mastectomy. 122 (83%) patients received systemic chemotherapy. 20 (14%) patients developed local and/or distant metastatses involving lungs, brain, bone and liver within 3–23 months of their initial diagnosis and 1 patient a second primary. 20 women (14%) died in 3–26 month from their initial diagnosis. Conclusion: Currently there is no specific regimen for the treatment of TN breast cancer. Despite being sensitive to anthracycline, taxanes and platinum, there is high early recurrence and mortality with TN breast cancer. On-going research to identify targeted therapy will help to find a better treatment for this subset of patients. Our goal for our predominantly AA patients at WCI is to initiate TN targeted clinical trials and determine targets for future therapy. No significant financial relationships to disclose." @default.
• W2272129917 created "2016-06-24" @default.
• W2272129917 creator A5067203408 @default.
• W2272129917 creator A5073754557 @default.
• W2272129917 date "2008-05-20" @default.
• W2272129917 modified "2023-10-17" @default.
• W2272129917 title "Triple-negative breast cancer at Washington Cancer Institute (WCI)" @default.
• W2272129917 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.22207" @default.
• W2272129917 hasPublicationYear "2008" @default.
• W2272129917 type Work @default.
• W2272129917 sameAs 2272129917 @default.
• W2272129917 citedByCount "0" @default.
• W2272129917 crossrefType "journal-article" @default.
• W2272129917 hasAuthorship W2272129917A5067203408 @default.
• W2272129917 hasAuthorship W2272129917A5073754557 @default.
• W2272129917 hasConcept C120665830 @default.
• W2272129917 hasConcept C121332964 @default.
• W2272129917 hasConcept C121608353 @default.
• W2272129917 hasConcept C126322002 @default.
• W2272129917 hasConcept C143998085 @default.
• W2272129917 hasConcept C146357865 @default.
• W2272129917 hasConcept C151730666 @default.
• W2272129917 hasConcept C2780110267 @default.
• W2272129917 hasConcept C29456083 @default.
• W2272129917 hasConcept C530470458 @default.
• W2272129917 hasConcept C61511704 @default.
• W2272129917 hasConcept C71924100 @default.
• W2272129917 hasConcept C72563966 @default.
• W2272129917 hasConcept C84606932 @default.
• W2272129917 hasConcept C86803240 @default.
• W2272129917 hasConcept C90924648 @default.
• W2272129917 hasConceptScore W2272129917C120665830 @default.
• W2272129917 hasConceptScore W2272129917C121332964 @default.
• W2272129917 hasConceptScore W2272129917C121608353 @default.
• W2272129917 hasConceptScore W2272129917C126322002 @default.
• W2272129917 hasConceptScore W2272129917C143998085 @default.
• W2272129917 hasConceptScore W2272129917C146357865 @default.
• W2272129917 hasConceptScore W2272129917C151730666 @default.
• W2272129917 hasConceptScore W2272129917C2780110267 @default.
• W2272129917 hasConceptScore W2272129917C29456083 @default.
• W2272129917 hasConceptScore W2272129917C530470458 @default.
• W2272129917 hasConceptScore W2272129917C61511704 @default.
• W2272129917 hasConceptScore W2272129917C71924100 @default.
• W2272129917 hasConceptScore W2272129917C72563966 @default.
• W2272129917 hasConceptScore W2272129917C84606932 @default.
• W2272129917 hasConceptScore W2272129917C86803240 @default.
• W2272129917 hasConceptScore W2272129917C90924648 @default.
• W2272129917 hasIssue "15_suppl" @default.
• W2272129917 hasLocation W22721299171 @default.
• W2272129917 hasOpenAccess W2272129917 @default.
• W2272129917 hasPrimaryLocation W22721299171 @default.
• W2272129917 hasRelatedWork W1966181922 @default.
• W2272129917 hasRelatedWork W1999292713 @default.
• W2272129917 hasRelatedWork W2043165423 @default.
• W2272129917 hasRelatedWork W2050936961 @default.
• W2272129917 hasRelatedWork W2375815296 @default.
• W2272129917 hasRelatedWork W2554176272 @default.
• W2272129917 hasRelatedWork W2584184160 @default.
• W2272129917 hasRelatedWork W2953241133 @default.
• W2272129917 hasRelatedWork W3198519606 @default.
• W2272129917 hasRelatedWork W4205578220 @default.
• W2272129917 hasVolume "26" @default.
• W2272129917 isParatext "false" @default.
• W2272129917 isRetracted "false" @default.
• W2272129917 magId "2272129917" @default.
• W2272129917 workType "article" @default.